Showing results (11-20 of 2,355) with videos related to
Sort By:
Pageof 236
Clinical Neuropharmacology|July 28, 2010
Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alphaFrancis E Lotrich, Robert E Ferrell, Mordechai Rabinovitz, et al.Clinical Neuropharmacology|May 27, 2010
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group studyVincent Ries, Roland Selzer, Tobias Eichhorn, et al.Clinical Neuropharmacology|September 21, 2010
Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literatureBeth E Crowner, Diego Torres-Russotto, Alexandre R Carter, et al.Clinical Neuropharmacology|September 21, 2010
The effect of a clinically practical exercise on levodopa bioavailability and motor response in patients with Parkinson diseaseGiovanna Lopane, Manuela Contin, Cesa Scaglione, et al.Clinical Neuropharmacology|June 1, 1991
An open trial of buspirone in migraine prophylaxis. Preliminary reportJ Pascual, J BercianoClinical Neuropharmacology|January 1, 1990
Alternative prophylactic treatments to lithium in bipolar disordersM C Mauri, M Percudani, M G Regazzetti, et al.Clinical Neuropharmacology|June 1, 1991
The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's diseaseM J Steiger, F Stocchi, A Carta, et al.Clinical Neuropharmacology|January 1, 1990
Metabolic and circulatory evaluation of cerebral ischemic accident in humans by positron emission tomography: a pilot study with almitrine-raubasineJ C Depresseux, G Franck, H Van Cauwenberge, et al.Clinical Neuropharmacology|September 15, 2010
Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating δ9-tetrahydrocannabinolJoshua A Lile, Thomas H Kelly, Lon R HaysPageof 236